作者：
Pirosa, Maria Cristina;Stathis, Anastasios;Zucca, Emanuele
通讯作者：
Pirosa, MC
作者机构：
Oncol Inst Southern Switzerland, Clin Med Oncol, Bellinzona, Switzerland.
Inst Oncol Res, Bellinzona, Switzerland.
Univ Svizzera Italiana, Fac Biomed Sci, Lugano, Switzerland.
Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Clin Med Oncol, Ente Osped Cantonale, Via A Gallino 12, CH-6500 Bellinzona, Switzerland.
通讯机构：
Osped Reg Bellinzona & Valli, Oncol Inst Southern Switzerland, Clin Med Oncol, Ente Osped Cantonale, Via A Gallino 12, CH-6500 Bellinzona, Switzerland.
语种：
英文
关键词：
DLBCL,relapsed-refractory disease,monoclonal antibodies,Anti CD-19 agent,Tafasitamab
期刊：
Human Vaccines & Immunotherapeutics
ISSN：
2164-5515
年：
2024
卷：
20
期：
1
页码：
2309701
摘要：
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new treatments have been developed and approved for these patients, among them of particular relevance are those targeting CD19. Tafasitamab is a humanized monoclonal antibody targeting CD19, composed of a modified fragment crystallizable (Fc) region engineered with higher affinity for Fc gamma receptors (Fc gamma R) receptors, leading to increased cytotoxicity through natural killer cells and macrophages (antibody-d...
